Impact of immunosuppressive therapy on hepatitis B vaccination in inflammatory bowel diseases

European Journal of Gastroenterology and Hepatology

Volumn 27, Issue 8, 2015, Pages 877-881

  Belle, Arthur ^a   Baumann, Cédric ^b   Bigard, Marc André ^a   Zallot, Camille ^a   Gizard, Emmanuel ^a   Guéant, Jean Louis ^a   Bronowicki, Jean Pierre ^a   Peyrin Biroulet, Laurent ^a  

^a UNIVERSITY HOSPITAL OF NANCY   (France)

^b UNIVERSITÉ DE LORRAINE   (France)

Author keywords

hepatitis B; immunosuppressive; inflammatory bowel disease; vaccination

Indexed keywords

ADALIMUMAB; CORE PROTEIN; HEPATITIS B SURFACE ANTIBODY; HEPATITIS B SURFACE ANTIGEN; INFLIXIMAB; MERCAPTOPURINE; METHOTREXATE; RECOMBINANT HEPATITIS B VACCINE; HEPATITIS B ANTIBODY; HEPATITIS B VACCINE; IMMUNOSUPPRESSIVE AGENT;

ADULT; ARTICLE; BODY MASS; COHORT ANALYSIS; COMPARATIVE STUDY; CONTROLLED STUDY; CROHN DISEASE; DRUG EFFICACY; FEMALE; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; TERMINAL ILEUM; ULCERATIVE COLITIS; VACCINATION; BLOOD; IMMUNIZATION; IMMUNOCOMPROMISED PATIENT; IMMUNOLOGY; INFLAMMATORY BOWEL DISEASES; MIDDLE AGED; TIME FACTOR; TREATMENT OUTCOME; YOUNG ADULT;

ADULT; FEMALE; HEPATITIS B; HEPATITIS B ANTIBODIES; HEPATITIS B SURFACE ANTIGENS; HEPATITIS B VACCINES; HUMANS; IMMUNIZATION SCHEDULE; IMMUNOCOMPROMISED HOST; IMMUNOSUPPRESSIVE AGENTS; INFLAMMATORY BOWEL DISEASES; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; TIME FACTORS; TREATMENT OUTCOME; VACCINATION; YOUNG ADULT;

EID: 84938497746     PISSN: 0954691X     EISSN: 14735687     Source Type: Journal    
DOI: 10.1097/MEG.0000000000000370     Document Type: Article

References (40)

1. Lok AS, McMahon BJ. Chronic hepatitis B. Hepatology 2007; 45:507-539.
2. European Association For The Study Of The Liver. EASL Clinical Practice Guidelines: management of chronic hepatitis B. J Hepatol 2009; 50:227-242.
3. Hou JK, Velayos F, Terrault N, Mahadevan U. Viral hepatitis and inflammatory bowel disease. Inflamm Bowel Dis 2010; 16:925-932.
4. Gisbert JP, Chaparro M, Esteve M. Review article: prevention and management of hepatitis B and C infection in patients with inflammatory bowel disease. Aliment Pharmacol Ther 2011; 33:619-633.
5. Del Valle García-Sánchez M, Gómez-Camacho F, Poyato-González A, Iglesia-Flores EM, De Dios-Vega JF, Sancho-Zapatero R. Infliximab therapy in a patient with Crohn's disease and chronic hepatitis B virus infection. Inflamm Bowel Dis 2004; 10:701-702.
6. Peyrin-Biroulet L, Oussalah A, Williet N, Pillot C, Bresler L, Bigard MA. Impact of azathioprine and tumour necrosis factor antagonists on the need for surgery in newly diagnosed Crohn's disease. Gut 2011; 60:930-936.
7. Williet N, Pillot C, Ousallah A, Billioud V, Chevaux JB, Bresler L, et al. Incidence of and impact of medications on colectomy in newly diagnosed ulcerative colitis in the era of biologics. Inflamm Bowel Dis 2012; 18:1641-1646.
8. Esteve M, Saro C, Gonzalez-Huix F, Suarez F, Forné M, Viver JM. Chronic hepatitis B reactivation following infliximab therapy in Crohn's disease patients: need for primary prophylaxis. Gut 2004; 53:1363-1365.
9. Ueno Y, Tanaka S, Shimamoto M, Miyanaka Y, Hiyama T, Ito M, et al. Infliximab therapy for Crohn's disease in a patient with chronic hepatitis B. Dig Dis Sci 2005; 50:163-166.
10. Millonig G, Kern M, Ludwiczek O, Nachbaur K, Vogel W. Subfulminant hepatitis B after infliximab in Crohn's disease: need for HBV-screening? World J Gastroenterol 2006; 12:974-976.
11. Colbert C, Chavarria A, Berkelhammer C. Fulminant hepatic failure in chronic hepatitis B on withdrawal of corticosteroids, azathioprine and infliximab for Crohn's disease. Inflamm Bowel Dis 2007; 13:1453-1454.
12. Esteve M, Loras C, Gonzalez-Huix F. Lamivudine resistance and exacerbation of hepatitis B in infliximab-treated Crohn's disease patient. Inflamm Bowel Dis 2007; 13:1450-1451.
13. Madonia S, Orlando A, Scimeca D, Olivo M, Rossi F, Cottone M. Occult hepatitis B and infliximab-induced HBV reactivation. Inflamm Bowel Dis 2007; 13:508-509.
14. Ojiro K, Naganuma M, Ebinuma H, Kunimoto H, Ogata H, Iwao Y, et al. Reactivation of hepatitis B in a patient with Crohn's disease treated using infliximab. J Gastroenterol 2008; 43:397-401.
15. Loras C, Gisbert JP, Minguez M, Merino O, Bujanda L, Saro C, et al. Liver dysfunction related to hepatitis B and C in patients with inflammatory bowel disease treated with immunosuppressive therapy. Gut 2010; 59:1340-1346.
16. Belle A, Bronowicki JP, Peyrin-Biroulet L. Reactivation of viral hepatitis in immunosuppressed patients: an ounce of prevention is worth a pound of cure. Gastroenterology 2011; 140:360-362.
17. Chevaux JB, Nani A, Oussalah A, Venard V, Bensenane M, Belle A, et al. Prevalence of hepatitis B and C and risk factors for nonvaccination in inflammatory bowel disease patients in Northeast France. Inflamm Bowel Dis 2010; 16:916-924.
18. Papa A, Felice C, Marzo M, Andrisani G, Armuzzi A, Covino M, et al. Prevalence and natural history of hepatitis B and C infections in a large population of IBD patients treated with anti-tumor necrosis factor agents. J Crohns Colitis 2013; 7:113-119.
19. Katsanos KH, Tsianos VE, Zois CD, Zioga H, Vagias I, Zervou E, et al. Inflammatory bowel disease and hepatitis B and C in Western Balkans: a referral centre study and review of the literature. J Crohns Colitis 2010; 4:450-465.
20. Loras C, Saro C, Gonzalez-Huix F, Minquez M, Merino O, Gisbert JP, et al. Prevalence and factors related to hepatitis B and C in inflammatory bowel disease patients in Spain: a nationwide, multicenter study. Am J Gastroenterol 2009; 104:57-63.
21. Rahier JF, Ben-Horin S, Chowers Y, Conlon C, De Munter P, D'Haens G, et al. European evidence-based consensus on the prevention, diagnosis and management of opportunistic infections in inflammatory bowel disease. J Crohns Colitis 2009; 3:47-91.
22. WHO Publication. Hepatitis B vaccines: WHO position paper-recommendations. Vaccine 2010; 28:589-590.
23. Coates T, Wilson R, Patrick G, André F, Watson V. Hepatitis B vaccines: assessment of the seroprotective efficacy of two recombinant DNA vaccines. Clin Ther 2001; 23:392-403.
24. Mast EE, Weinbaum CM, Fiore AE, Alter MJ, Bell BP, Finelli L, et al. A comprehensive immunization strategy to eliminate transmission of hepatitis B virus infection in the United States: recommendations of the Advisory Committee on Immunization Practices (ACIP). Part II: immunization of adults. MMWR Recomm Rep 2006; 55:1-33.
25. Shouval D. Hepatitis B vaccines. J Hepatol 2003; 39 (Suppl 1): S70-S76.
26. Gisbert JP, Menchén L, García-Sánchez V, Marin I, Villagrasa JR, Chaparro M. Comparison of the effectiveness of two protocols for vaccination (standard and double dosage) against hepatitis B virus in patients with inflammatory bowel disease. Aliment Pharmacol Ther 2012; 35:1379-1385.
27. Gisbert JP, Villagrasa JR, Rodriguez-Nogueiras A, Chaparro M. Efficacy of hepatitis B vaccination and revaccination and factors impacting on response in patients with inflammatory bowel disease. Am J Gastroenterol 2012; 107:1460-1466.
28. Altunöz ME, Senates E, Yesil A, Calhan T, Ovünç AO. Patients with inflammatory bowel disease have a lower response rate to HBV vaccination compared to controls. Dig Dis Sci 2012; 57:1039-1044.
29. Urganci N, Kalyoncu D. Immunogenecity of hepatitis A and B vaccination in pediatric patients with inflammatory bowel disease. J Pediatr Gastroenterol Nutr 2013; 56:412-415.
30. Gisbert JP, Villagrasa JR, Rodríguez-Nogueiras A, Chaparro M. Kinetics of anti-hepatitis B surface antigen titers after hepatitis B vaccination in patients with inflammatory bowel disease. Inflamm Bowel Dis 2013; 19:554-558.
31. Peyrin-Biroulet L, Pillot C, Oussalah A, Billioud V, Aissa N, Balde M, et al. Urinary tract infections in hospitalized inflammatory bowel disease patients: a 10-year experience. Inflamm Bowel Dis 2012; 18:697-702.
32. Williet N, Pillot C, Oussalah A, Billioud V, Chevaux JB, Bresler L, et al. Incidence of and impact of medications on colectomy in newly diagnosed ulcerative colitis in the era of biologics. Inflamm Bowel Dis 2012; 18:1641-1646.
33. Peyrin-Biroulet L, Oussalah A, Williet N, Pillot C, Bresler L, Bigard MA. Impact of azathioprine and tumour necrosis factor antagonists on the need for surgery in newly diagnosed Crohn's disease. Gut 2011; 60:930-936.
34. Melmed GY, Ippoliti AF, Papadakis KA, Tran TT, Birt JL, Lee SK, et al. Patients with inflammatory bowel disease are at risk for vaccinepreventable illnesses. Am J Gastroenterol 2006; 101:1834-1840.
35. Vida Perez L, Gomez Camacho F, Garcia Sanchez V, Iglesias Flores EM, Castillo Molina L, Cerezo Ruiz A, et al. Adequate rate of response to hepatitis B virus vaccination in patients with inflammatory bowel disease. Med Clin (Barc) 2009; 132:331-335.
36. Potsch DV, Camacho LA, Tuboi S, Villar LM, Miguel JC, Ginuino C, et al. Vaccination against hepatitis B with 4-double doses increases response rates and antibodies titers in HIV-infected adults. Vaccine 2012; 30:5973-5977.
37. Young MD, Gooch WM, Zuckerman AJ, Du W, Dickson B, Maddrey WC. Comparison of a triple antigen and a single antigen recombinant vaccine for adult hepatitis B vaccination. J Med Virol 2001; 64:290-298.
38. Sartor RB. Microbial influences in inflammatory bowel diseases. Gastroenterology 2008; 134:577-594.
39. Gersemann M, Wehkamp J, Stange EF. Innate immune dysfunction in inflammatory bowel disease. J Intern Med 2012; 271:421-428.
40. Daniel K, Podolsky MD. Inflammatory bowel disease. N Engl J Med 2002; 347:417-429.